1/1
2 files

Supplementary Figures – Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis

figure
posted on 07.02.2022, 14:04 authored by Figshare Future Science GroupFigshare Future Science Group, Jiarui Chen, Xingyu Liu, Junhong Zhang, Zhao Huang, Wei Zeng, Jing Hu, Gang Chen, Yan Gong, Yu Liu, Conghua Xie

Supplementary Figure S1. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis

Pairwise meta-analysis for first line therapy. Forestplot of PFS (a1), OS (a2) and ORR (a3) for overall population. Forestplot of PFS (b1), OS (b2) for PD-L1 negative population. Forestplot of PFS (c1), OS (c2) for PD-L1 intermediate population. Forestplot of PFS (d1), OS (d2) for PD-L1 high population. Forestplot of PFS (e1), OS (e2) for liver metastasis population. Forestplot of grade 3 to 5 tr-AEs (f). *PFS, progression free survival; OS, overall survival; ORR, objective response rate; PD-L1, program death ligand 1; tr-AEs, treatment-related adverse events.

Supplementary Figure S2–S11. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis

Funding

National Natural Science Foundation of China (81773236, 81800429 and 81972852)

Key Research & Development Project of Hubei Province (2020BCA069)

Nature Science Foundation of Hubei Province (2020CFB612)

Health Commission of Hubei Province Medical Leading Talent Project, Young and Middle-Aged Medical Backbone Talents of Wuhan (WHQG201902)

Application Foundation Frontier Project of Wuhan (2020020601012221)

Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (znpy2019001, znpy2019048, and ZNJC201922)

Chinese Society of Clinical Oncology Top Alliance Tumor Immune Research Fund (Y-JS2019-036)

History